LNK001 for Advanced Kidney Cancer After Prior Treatments
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 1 trial tests a new cell therapy called LNK001 in patients with advanced clear-cell kidney cancer that has progressed despite prior immunotherapy and targeted drugs. The therapy is designed to recognize and attack cancer cells by targeting a protein called CAIX.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with advanced or metastatic clear-cell renal cell carcinoma (kidney cancer)
- Received at least two prior treatments: one immune checkpoint inhibitor (like pembrolizumab or nivolumab) and one tyrosine kinase inhibitor (like sunitinib or pazopanib)
- Cancer cells must test positive for a protein called CAIX (≥50% expression) on a biopsy
- At least one measurable tumor lesion visible on imaging (CT or MRI)
- Good overall health and organ function (blood counts, liver, kidney tests within acceptable ranges)
- Age 18 or older and able to commit to long-term follow-up (15 years) after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests an investigational medicine called HS-IT101 for people with advanced kidney cancer that hasn't responded to standard treatments. The goal is to see if this new therapy can help shrink or control the cancer.
This trial tests a new treatment made from your own immune cells, modified to target a protein called CA9 that is common on clear cell kidney cancer cells. The cells are injected directly into a tumor, and the goal is to see if this can shrink the tumor or slow its growth.
This trial tests a new type of immune cell therapy (CAR NK cells) that targets a protein called CD70 on kidney cancer cells. It's for people with advanced clear cell kidney cancer that hasn't responded to standard treatments.
This trial tests a new type of cell therapy (CAR-NK cells) designed to target kidney cancer that has spread or cannot be removed with surgery. The cells are engineered in the lab to recognize and attack cancer cells, and may help patients whose cancer has grown despite previous treatments.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.